Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

被引：36

作者：

Larsen, T. S. ^{[1
,3
]}

Bjerrum, O. W. ^{[2
]}

Pallisgaard, N. ^{[3
]}

Andersen, M. T. ^{[2
]}

Moller, M. B. ^{[3
]}

Hasselbalch, H. C. ^{[1
]}

机构：

[1] Odense Univ Hosp, Dept Haematol, DK-5000 Odense C, Denmark

[2] Rigshosp, Dept Haematol, DK-2100 Copenhagen, Denmark

[3] Odense Univ Hosp, Dept Pathol, DK-5000 Odense C, Denmark

来源：

ANNALS OF HEMATOLOGY | 2008年 / 87卷 / 10期

关键词：

polycythemia vera; interferon; PCR; JAK2; remission;

D O I：

10.1007/s00277-008-0498-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response.

引用

页码：847 / 850

页数：4

共 12 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2] Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders [J].

Bonifazi, F ;

de Vivo, A ;

Rosti, G ;

Guilhot, F ;

Guilhot, J ;

Trabacchi, E ;

Hehlmann, R ;

Hochhaus, A ;

Shepherd, PCA ;

Steegmann, JL ;

Kluin-Nelemans, HC ;

Thaler, J ;

Simonsson, B ;

Louwagie, A ;

Reiffers, J ;

Mahon, FX ;

Montefusco, E ;

Alimena, G ;

Hasford, J ;

Richards, S ;

Saglio, G ;

Testoni, N ;

Martinelli, G ;

Tura, S ;

Baccarani, M .

BLOOD, 2001, 98 (10) :3074-3081

[3] Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-α 2a in a patient with polycythemia vera [J].

Ishii, T. ;

Xu, M. ;

Zhao, Y. ;

Hu, W-Y ;

Ciurea, S. ;

Bruno, E. ;

Hoffman, R. .

LEUKEMIA, 2007, 21 (02) :373-374

[4] Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha [J].

Jones, AV ;

Silver, RT ;

Waghorn, K ;

Curtis, C ;

Kreil, S ;

Zoi, K ;

Hochhaus, A ;

Oscier, D ;

Metzgeroth, G ;

Lengfelder, E ;

Reiter, A ;

Chase, AJ ;

Cross, NCP .

BLOOD, 2006, 107 (08) :3339-3341

[5] High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a [J].

Kiladjian, Jean-Jacques ;

Cassinat, Bruno ;

Turlure, Pascal ;

Cambier, Nathalie ;

Roussel, Murielle ;

Bellucci, Sylvia ;

Menot, Marie-Laurence ;

Massonnet, Gerald ;

Dutel, Jean-Luc ;

Ghomari, Kamel ;

Rousselot, Philippe ;

Grange, Marie-Jose ;

Chait, Yasmina ;

Vainchenker, William ;

Parquet, Nathalie ;

Abdelkader-Aljassem, Lina ;

Bernard, Jean-Francois ;

Rain, Jean-Didier ;

Chevret, Sylvie ;

Chomienne, Christine ;

Fenaux, Pierre .

BLOOD, 2006, 108 (06) :2037-2040

[6] Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow [J].

Larsen, T. S. ;

Pallisgaard, N. ;

Moller, M. B. ;

Hasselbalch, H. C. .

LEUKEMIA, 2008, 22 (01) :194-195

[7] The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders [J].

Larsen, Thomas Stauffer ;

Christensen, Jacob Haaber ;

Hasselbalch, Hans Carl ;

Pallisgaard, Niels .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (05) :745-751

[8] CYTOGENETIC CONVERSION IN A CASE OF POLYCYTHEMIA-VERA TREATED WITH INTERFERON-ALPHA [J].

MESSORA, C ;

BENSI, L ;

VECCHI, A ;

LONGO, R ;

GIACOBBI, F ;

TEMPERANI, P ;

BEVINI, M ;

EMILIA, G ;

SACCHI, S .

BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (02) :402-404

[9]

Samuelsson J, 2006, HAEMATOLOGICA, V91, P1281

[10] A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia -: Feasibility, clinical and biologic effects, and impact, on quality of life [J].

Samuelsson, Jan ;

Hasselbalch, Hans ;

Bruserud, Oystein ;

Temerinac, Snezana ;

Brandberg, Yvonne ;

Merup, Mats ;

Linder, Olle ;

Bjorkholm, Magnus ;

Pahl, Heike L. ;

Birgegard, Gunnar .

CANCER, 2006, 106 (11) :2397-2405

← 1 2 →